Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer

NCT02278055 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

29

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Prostate Cancer
Pain

Interventions

DRUG: Radium-223

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]